Unicycive Therapeutics, Inc. (UNCY) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Unicycive Therapeutics, Inc.

UNCY

NASDAQ

Unprofitable

66M

Biotechnology

Next Earning date - 12 May 2025

66M

Biotechnology

Next Earning date - 12 May 2025

0.64USD

0.00 ( 0.00%)

Market Closed (as of Apr 25, 20:00 EDT)

Relative Strenght

Volume Buzz

-78%

Earning Acce

Dist 52w H.

50%

Overview Chart

Quote Panel

Updated April 27, 2025

1W 4.90 % 1M 4.23 % 3M 18.74 % 1Y -47.54 %

Key Metrics

Market Cap
66.43M
Shares Outstanding
103.80M
Share in Float
86.07M
Dividende
0

Earning Date
12 May 2025
Price Target
0.64
Average Volume
965391
Beta
2.147

Range
0.202-1.289
Industry
Biotechnology
Website
https://www.unicycive.com
Sector
Healthcare

Quote Panel

Updated April 27, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

57.69x

P/B Ratio

0.1

Debt/Equity

0.0%

Net Margin

$-0.6

EPS

How UNCY compares to sector?

P/E Ratio

Fundamentals

Relative Strength

UNCY

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

UNCY

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$20M

NaN%

2025-Revenue

$0.22

-579%

2025-EPS

$4M

119%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Piper Sandler

initialise

Previous: Not converted

2024-04-04

Now: Overweight

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-0.29
vs -0.24

Q2.23

N/A

-0.29
vs -0.24

Q3.23

N/A

-0.13
vs -0.37

Q4.23

N/A

-0.16
vs -0.35

Q1.24

N/A

-0.27
vs -0.29

Q2.24

N/A

-0.15
vs -0.29

Q3.24

+100%

NA
vs -0.13

Q4.24

N/A

-0.16
vs -0.16

Q1.25

N/A

-0.07
vs -0.27

Q2.25

N/A

-0.08
vs -0.15

Sales Growth

YoY

Current

Estimates

Q3.22

951K vs NA

Q4.22

NA vs NA

Q1.23

675K vs NA

Q2.23

NA vs NA

Q3.23

-100%

NA vs 951K

Q4.23

-271000.00 vs NA

Q1.24

-100%

NA vs 675K

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

+100%

NA vs -271000

Return on Equity

QoQ

Q1.23

-239%

-2.39
vs 11.44

Q2.23

-56%

-0.56
vs -2.39

Q3.23

-128%

-1.28
vs -0.56

Q4.23

+205%

2.05
vs -1.28

Q1.24

+86%

0.86
vs 2.05

Q2.24

+13%

0.13
vs 0.86

Q3.24

-15%

-0.15
vs 0.13

Q4.24

-290%

-2.90
vs -0.15

Institutionnal Ownership

QoQ

Q1.23

13
vs 9

44%

Q2.23

15
vs 13

15%

Q3.23

16
vs 15

Q4.23

16
vs 16

Q1.24

23
vs 16

44%

Q2.24

24
vs 23

Q3.24

28
vs 24

17%

Q4.24

30
vs 28

Earnings Growth

Latest News

globenewswire.com

7 hours ago

Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

globenewswire.com

7 hours ago

Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

globenewswire.com

7 hours ago

Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia

globenewswire.com

7 hours ago

Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360

globenewswire.com

7 hours ago

Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science

globenewswire.com

7 hours ago

Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

Company Description

0.64USD

N/A

0.00x

57.69x

0.1

0.0%

$-0.6

$20M

$0.22

$4M

Earnings Growth

Latest News

Latest News

Latest News

$20M

$0.22

$4M

Company Description

0.64USD

N/A

0.00x

57.69x

0.1

0.0%

$-0.6